Conatus Pharmaceuticals (CNAT) Tops Q4 EPS by 2c

Conatus Pharmaceuticals (NASDAQ: CNAT) reported Q4 EPS of ($0.15), $0.02 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $8.8 million versus the consensus estimate of $9.49 million.

For earnings history and earnings-related data on Conatus Pharmaceuticals (CNAT) click here.

You May Also Be Interested In

• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
• Securitize Corp (SECZ) PT Lowered to $10 at Benchmark as Stock Plummets Post Q2 Earnings
• Smith-Midland Corporation (SMID) Tops Q2 EPS by 26c